BioSpace News Archive

Synaptive Medical Inc., a global med tech and technology company solving surgical, imaging and data challenges, will showcase its near-infrared fluorescence visualization setting, Modus IR, at this year’s American Association of Neurological Surgeons (AANS) meeting, taking place in Chicago, Illinois, from May 3 – 6.

The global proteomics market size was evaluated at US$ 31.55 billion in 2023 and is expected to attain around US$ 110.13 billion by 2032, growing at a CAGR of 14.9% from 2023 to 2032

Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, announced the completion of a £12.8m seed funding round led by Octopus Ventures.

BioSig Technologies, Inc. or, a medical technology Company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, announced the appointment of Mr. Anthony Amato to the Position of Chief Executive Officer, effective immediately. Additionally, Mr. Amato will serve on the Company’s Board of Directors, which is currently being assembled.

Intego Clinical, a biometrics Clinical Research Organization (CRO) that helps leading life science companies

Orchestra BioMed Holdings, Inc., a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced the patent estate related to AVIM Therapy has reached 110 patents worldwide.

Inflammatory bowel disease is a common chronic gastrointestinal disorder and current treatment strategies can cause adverse effects.

Allurion Technologies, Inc. today announced preliminary, unaudited results for the first quarter 2024.

Tenon Medical, Inc. today announced plans to release financial results for the first quarter 2024 ended March 31, 2024 after market close on Tuesday, May 14, 2024.

Shenzhen Chipscreen Biosciences Co., Ltd. announced that the company’s lead innovative product Chidamide, an oral subtype-selective histone deacetylase inhibitor, combined with R-CHOP, has been officially approved by the National Medical Products Administration for treatment of previously untreated diffuse large B-cell lymphoma with positive MYC and BCL2 expression.